An observational study in Skin Lesion, Melanoma and Moles, sponsored by Orlucent, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-11-19.
Sponsored by Orlucent, Inc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 269 studies in Melanoma with a site in United Kingdom — 31 open to participants now, 73 under way, 24 of them phase 3. Melanoma · United Kingdom.
Among the 269 studies in Melanoma with a site in United Kingdom, this one is the 27th largest by enrollment of the 41 observational ones that give a count, is one of 16 that started in 2018, is one of 41 observational ones, and was the 137th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →31 of the 269 studies in Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+
Mitra Bio · Sites in United Kingdom, Belgium, Germany and 1 more country
Ages 18+
IDEAYA Biosciences · Sites in United Kingdom, United States, Australia and 18 more countries
Ages 18+
Cancer Research UK · Sites in United Kingdom
Melanoma Institute Australia · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 108 · Phase 3 80
First in 1989; this study’s year is marked. 16 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 183 across the 226 interventional studies, 400 across the 41 observational. Of the 172 that completed or were terminated, 96 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 269 have an industry lead sponsor. The 10 most frequent:
Orlucent, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Orlucent, Inc has 3 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Melanoma with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 14 to your calendar (.ics) → With an account.
Among the 269 studies in Melanoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the clinical utility of the Melanoma Detection System (MDS).
The purpose of this study is to establish the clinical utility of the MDS while continuing to evaluate the safety and performance of the MDS in patients with skin lesions who are referred to secondary care clinics for evaluation, whose lesions (moles) are suspicious for melanoma.
Subjects referred to a specialist for possible presence of melanoma in skin lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
Diagnostic Test: Melanoma Detection System -MDS
Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
Diagnostic Test: Melanoma Detection System -MDS
Imaging of lesion using the MDS test.
Also known as: MDS
Utility of the MDS in determining urgent or non-urgent excision of moles.
The MDS will provide a score that reflects the possibility for the presence of melanoma in moles. The score will be used together with clinical evaluation.
Time frame: 1 day
Does the MDS have an additive value to clinical evaluation of moles.
Does the MDS system provide superior results when compared to clinical evaluation.
Time frame: 1 day
User feedback for clinical use of the MDS in the clinical management of moles.
To gain feedback from users on how to best incorporate the MDS testing procedure in the clinical setting.
Time frame: 1 day
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Oct 2020, 30 months.
Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's 30 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlucent, Inc